1. Summarize outcomes of mutation directed upfront therapy of AML on IDH2 mutated patients on the Beat AML MASTER trial

2. Analyze racial disparities in outcomes of young patients with acute myeloid leukemia

3. Outline predictors of long term PFS in young ALL patients treated with CAR-T treatment

4. Name the most relevant benign hematology studies presented in ASH 2020 meeting 

  5. Explain the future application of gene therapy in sickle cell disease, use of mycophoenolate with steroids in first line ITP and tranexamic acid during treatment of    hematologic malignancies

Event address for attendees: https://uwmadison.webex.com/uwmadison/onstage/g.php?MTID=e0058833b45dd2e52d9653b9cda61e3bf

Session date: 
01/20/2021 - 8:00am to 9:00am CST
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours

Please login or register to take this course.
Discloser List CME Internal Report
Dr. Aric Hall
Dr. Moniba Nazeef